Doxazosin Tablet
Product Images NDC 55154-7996

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 55154-7996). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bag Label (08521333 Ff21 45ad B99e 1f43d945d24d 00)

Label for Doxazosin Tablets USP 2 mg, package of 10 tablets. It includes the NDC number 55154-7996-0, usage notes, storage instructions, and dispensing warnings. Manufactured by Apotex, Inc. in Toronto, Canada, for Apotex Corp., distributed by Major Pharmaceuticals in Livonia, MI, and Cardinal Health in Dublin, OH.*

FDA Label Image

Doxazosin-structure (Doxazosin Structure)

Chemical structure of Doxazosin, the active ingredient shown in the image as a molecular diagram with rings, nitrogen atoms, and functional groups including methoxy and sulfonic acid components.*

FDA Label Image

Figure1.jpg (Figure1)

This image contains two line graphs showing clinical data for Doxazosin compared to placebo over a 14-week treatment period. The left graph displays mean change in total symptom score from baseline, with Doxazosin showing greater symptom reduction than placebo. The right graph shows mean increase in maximum urinary flow rate (mL/sec) from baseline, with Doxazosin demonstrating higher flow rate improvement than placebo. Both graphs include error bars and sample sizes (N=50 for Doxazosin, N=47 for placebo).*

FDA Label Image

Table3.jpg (Table3)

Data table and bar chart summarizing effectiveness data from placebo-controlled trials of doxazosin, including symptom scores and maximum flow rates. The table presents mean baseline and mean change values for symptom score and maximum flow rate across three studies comparing placebo and doxazosin doses. The adjacent bar chart visualizes maximum flow rate improvements and symptom score changes for placebo, 4 mg, and 8 mg doxazosin in Study 2.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.